Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Shuanggang Chen, Mengting Shi, Lujun Shen, Han Qi, Weiqi Wan, Fei Cao, Lin Xie, Ying Wu, Guanjian Chen, Jinqing Mo, Guolian Zhu, Dongdong Ye, Yinqi Zhang, Ziqing Feng, Li Xu & Weijun Fan. (2020) Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis. International Journal of Hyperthermia 37:1, pages 384-391.
Read now
Read now
Zhiyu Qiu, Lujun Shen, Shuanggang Chen, Han Qi, Fei Cao, Lin Xie & Weijun Fan. (2019) Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma：A Propensity Score Matching Analysis. Cancer Management and Research 11, pages 9321-9330.
Read now
Read now
Zeran Yang, Guang Chen, Ye Cui, Guowen Xiao, Tianhao Su, Jianan Yu, Zhiyuan Zhang, Yanjing Han, Kailan Yang & Long Jin. (2019) The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study. Cancer Biology & Therapy 20:3, pages 321-327.
Read now
Read now
Man Wu, Guanren Zhao, Xiaomei Zhuang, Tianhong Zhang, Ce Zhang, Wenpeng Zhang & Zhenqing Zhang. (2018) Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells. OncoTargets and Therapy 11, pages 2945-2954.
Read now
Read now
Articles from other publishers (13)
Ruihua Duan, Fen Gong, Yan Wang, Caixia Huang, Jiaming Wu, Leihao Hu, Min Liu, Shijun Qiu, Liming Lu & Yisheng Lin. (2023) Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis. World Journal of Surgical Oncology 21:1.
Crossref
Crossref
Shanshan Liu, Yunwei Han, Zhihong Zhang & Fei Wu. (2023) Effectiveness of c-TACE Combined With Sorafenib Versus c-TACE Monotherapy in Advanced Hepatocellular Carcinoma: A Retrospective Study. Clinical Medicine Insights: Oncology 17, pages 117955492211466.
Crossref
Crossref
Jincheng WangRui WuJin-yu SunFeifei LeiHuabing TanXiaojie Lu. (2022) An overview: Management of patients with advanced hepatocellular carcinoma. BioScience Trends 16:6, pages 405-425.
Crossref
Crossref
Shen Zhang, Wan-Sheng Wang, Bin-Yan Zhong & Cai-Fang Ni. (2022) Subsequent Treatment after Transarterial Chemoembolization Failure/Refractoriness: A Review Based on Published Evidence. Journal of Clinical and Translational Hepatology 10:4, pages 740-747.
Crossref
Crossref
Shen Zhang, Bin-Yan Zhong, Lei Zhang, Wan-Sheng Wang & Cai-Fang Ni. (2022) Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition. World Journal of Gastrointestinal Surgery 14:6, pages 528-537.
Crossref
Crossref
Dae Yang, Sunmin Park, Chai Rim, Won Yoon, In-Soo Shin & Han Lee. (2021) Salvage External Beam Radiotherapy after Incomplete Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review. Medicina 57:10, pages 1000.
Crossref
Crossref
Liyun Zheng, Shiji Fang, Fazong Wu, Weiqian Chen, Minjiang Chen, Qiaoyou Weng, Xulu Wu, Jingjing Song, Zhongwei Zhao & Jiansong Ji. (2021) Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. Frontiers in Molecular Biosciences 7.
Crossref
Crossref
Zhoujing Cheng, Lin He, Yingjie Guo, Yuhua Song, Shasha Song & Lijiu Zhang. (2020) The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis. World Journal of Surgical Oncology 18:1.
Crossref
Crossref
Pyeong Hwa Kim, Dong Il Gwon, Jong Woo Kim, Hee Ho Chu & Jin Hyoung Kim. (2020) The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization. European Radiology 30:10, pages 5650-5662.
Crossref
Crossref
Po-Ting Lin, Wei Teng, Wen-Juei Jeng, Yi-Chung Hsieh, Chen-Fu Hung, Chien-Hao Huang, Kar-Wai Lui, Yi-Cheng Chen, Chen-Chun Lin, Chun-Yen Lin, I-Shyan Sheen & Shi-Ming Lin. (2019) Add-on sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: a real-world experience. European Journal of Gastroenterology & Hepatology 32:9, pages 1192-1199.
Crossref
Crossref
Daniel H. Palmer, Katerina Malagari & Laura M. Kulik. (2020) Role of locoregional therapies in the wake of systemic therapy. Journal of Hepatology 72:2, pages 277-287.
Crossref
Crossref
Yuan Yao, Jianjian Chen, Dechao Jiao, Yahua Li, Xueliang Zhou & Xinwei Han. (2019) Elemene injection combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. Medicine 98:44, pages e17813.
Crossref
Crossref
David E. Kaplan, Rajni Mehta, Kathryn D’Addeo, Terence P. Gade & Tamar H. Taddei. (2018) Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching. Journal of Vascular and Interventional Radiology 29:4, pages 540-549.e4.
Crossref
Crossref